Trazodone hydrochloride tablets are indicated for the treatment of major depressive disorder (MDD) in adults. The mechanism of trazodone’s antidepressant action is not fully understood, but is thought to be related to its enhancement of serotonergic activity in the central nervous system (CNS).
Pharmacological Action
Trazodone functions as both a selective serotonin reuptake inhibitor (SSRI) and a 5HT2 receptor antagonist, with the net effect of this action on serotonergic transmission and its role in trazodone’s antidepressant effect remaining unknown. Preclinical studies demonstrate trazodone’s selective inhibition of neuronal serotonin reuptake (Ki = 367 nM) and antagonism at 5-HT2A serotonin receptors (Ki = 35.6 nM), alongside antagonism at 5-HT2B, 5-HT2C, α1A, α2C, and 5HT1A receptors. It also antagonizes alpha 1-adrenergic receptors, potentially contributing to postural hypotension.
Dosage and Administration
Absorption of trazodone hydrochloride is complete following oral administration, and food intake can influence absorption, affecting peak plasma concentrations and time to maximum concentration. Metabolism occurs primarily via CYP3A4, producing the active metabolite m-chlorophenylpiperazine (mCPP). Trazodone is extensively metabolized, with less than 1% excreted unchanged. Protein binding is high, approximately 89 to 95%. Clinical studies established trazodone’s efficacy and safety in inpatient and outpatient trials for MDD using the immediate-release formulation. Starting doses range from 150 mg daily, divided, with potential increases of 50 mg every three to four days, up to a maximum of 400 mg daily. Dosage adjustments are recommended based on clinical response and tolerance, with higher doses (up to 600 mg daily) considered for more severely depressed patients. Tablets should be taken shortly after a meal or light snack, and gradual dose reduction is advised upon discontinuation.